The International Society of Microbiota Annual Meeting will be held on October 19-21 in Paris, Sorbonne University, and online. The ISM will gather leaders and microbiota actors to discuss the recent advances, innovations and therapeutical strategies. Targeting Microbiota 2022 will put together many complementary talks and topics, controversies and clinical advances – from oral microbiota, to gut microbiota as well as vaginal microbiota.
Credit: International Society of Microbiota
The International Society of Microbiota Annual Meeting will be held on October 19-21 in Paris, Sorbonne University, and online. The ISM will gather leaders and microbiota actors to discuss the recent advances, innovations and therapeutical strategies. Targeting Microbiota 2022 will put together many complementary talks and topics, controversies and clinical advances – from oral microbiota, to gut microbiota as well as vaginal microbiota.
Among the hot topics which will be discussed:
- Microbiota & Microbiota Dysbiosis in Diseases: Recent Advances
- Nutrition, Water and Microbiota: The Missing Link
- Immunotherapy, Antibiotic Resistance, Cancer & Microbiota: Towards Personalized Medicine
- Strategies, Innovations & Challenges to Target Microbiota Dysbiosis
During these sessions, high-level speakers will cover many hot topics:
May the Microbiota of the Long-Lived Naked Mole-Rat Affect Human Health?
The naked mole-rat is a subterranean mouse-sized African mammal that shows astonishingly few age-related degenerative changes and seems to not be affected by cancer. These features make this wild rodent an excellent model to study the biology of healthy aging and longevity. Gerd Birkenmeier, University of Leipzig, Germany, and his team characterized for the first time the intestinal microbial ecosystem of the naked mole-rat in comparison to humans.
Interestingly, some compositional gut microbiota peculiarities were also shared with human gut microbial ecosystems of centenarians and Hadza hunter-gatherers, considered as models of a healthy gut microbiome and of a homeostatic and highly adaptive gut microbiota-host relationship, respectively. In addition, we found an enrichment of short-chain fatty acids and carbohydrate degradation products in naked mole-rat compared to human samples. The team has hope in using the FMT technique from the naked mole-rat to extend the lifespan of humans.
Gene Editing & Microbiome Therapy
Gene editing holds a promising future in microbiome therapy and exploring the complex interplay between members of the microbiome and our bodies. In this presentation, Nahla Mansour, National Research Center, Egypt, will highlight the re-emerging of gene editing tools and multiple strategies in microbiome therapy past, present, and future. She will describe the genetically engineered probiotic strains that have been constructed by her group, as well as their new project using CRISPR-Cas tools.
Probiotics and FMT as Add-on Therapies for Depression
Depression is a highly prevalent and burdensome psychiatric disorder. Even though antidepressants and further therapeutic approaches are widely applied, up to 30% of treatment-resistant patients experience residual symptoms when receiving optimized treatments. Therefore, the development of novel and more efficient treatment approaches is urgently needed.
In this talk, André Schmidt, University of Basel, Switzerland, presents data from a randomized controlled trial exploring clinical and biological effects along the MGB axis of probiotic supplementation in patients with depression. He further shows data from two depressed patients receiving fecal microbiota transplantation. These findings will be discussed in the view of current research and potential suggestions for future studies will be proposed aiming at developing microbial interventions for depression care.
Targeting Microbiota to Increase Cancer Immunotherapy Efficacy
Bertrand Routy, University of Montreal Hospital, Canada, explains that immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized the treatment for several cancers, including the most common lung cancer type, non-small cell lung cancer (NSCLC). However, only a minority of patients experience a long-lasting response and resistance to ICI treatment is common.
Recent efforts to increase the benefits of ICI to a greater majority of patients have involved strategies that target the gut microbiome to enhance the number of immune cells and their activity within the tumors, which translates into better outcome. Shifting the microbiome toward a more diverse and beneficial bacterial composition has also shown potential as a therapeutic approach to circumvent ICI resistance and enhance the immune T cell activity that promotes an ICI response.
Agenda, speakers, abstract submission and attendees
Submit your abstract before October 10.
More about the talks.
Access to all companies and academics who will attend.
More information about the registration process.
For more information about the ISM Annual Meeting & Conference, visit the ISM conference site or follow our social media: Facebook and LinkedIn.
